

1/37









Fig. 1

2/37

COMPOUND A




Fig. 2A

COMPOUND B





Fig. 2B



AGONIST Z

Fig. 3

Gli-1, GENE EXPRESSION IN THE LUNG




Fig. 4

Gli-1 EXPRESSION IS INVERSELY RELATED TO LUNG MATURATION




Fig. 5

6/37

COMPOUND B DOWNREGULATES mGli-1 IN LUNG EXPLANT CULTURES




Fig. 6

COMPOUND B TREATMENT INCREASES SURFACTANT TYPE C
PRODUCTION IN EMBRYONIC MOUSE LUNGS




Fig. 7

8/37

TYPE II PNEUMOCYTES IN COMPOUND B TREATED LUNG CULTURES
DIFFERENTIATE PREMATURELY




Fig. 8

9/37




Fig. 9

10/37




Fig. 10

Shh PROTEIN AND HEDGEHOG AGONIST Z




Fig. 11

BEST AVAILABLE COPY

12/37

BREAST CANCER Gli-1 In Situ HYBRIDIZATION-
EPITHELIAL EXPRESSION




Fig. 12

BEST AVAILABLE COPY




Fig. 13

PROSTATE CANCER Gli-1 In Situ HYBRIDIZATION-
STROMAL EXPRESSION

H & E



ANTISENSE



SENSE



Fig. 14

BPH Gli-1 In Situ HYBRIDIZATION-
STROMAL EXPRESSION




Fig. 15

HEDGEHOG SIGNALING IN MOUSE BLADDER

ptc-lacZ, NEWBORN



gli-1, ADULT




Fig. 16




Fig. 17

HH SIGNALING IN BLADDER CANCER CELL LINES (1d in 10% FBS, 2d in 1% FBS)

- | | |
|-------------|----------------|
| □ HT1376 | ▨ RT4 HTB-2 |
| ▨ SW780 | ▨ HT 1197 |
| ▨ J82 HTB-1 | ▨ TCCSUP HTB-5 |
| ▨ T24 HTB-4 | □ 5637 HTB-9 |




Fig. 18

HH SIGNALING IN BLADDER CANCER CELL LINES





Fig. 19

IN VITRO EFFICACY Gli-luc ASSAY

S12 FIBROBLAST CELL LINE WITH LUCIFERASE REPORTER



B. Flow-chart




Fig. 20

Gli-luc ASSAY ON BLADDER CANCER CELL LINES
(S12 + CANCER CELL CO-CULTURES, 1d IN 10% FBS, 2d IN 1% FBS)




Fig. 21

Gli-luc ASSAY ON RT-4

5E1, 24 hrs


 $IC_{50} = 85 \text{ ng/ml}$ $IC_{90} = 500 \text{ ng/ml}$

Fig. 22

RT-4 IN VIVO EFFICACY EXPERIMENT
RT-4 IN VIVO EXPERIMENT





Fig. 23

RT-4 IN VIVO EFFICACY EXPERIMENT

RT-4 IN VIVO EXPERIMENT TUMOR WEIGHTS



RT-4 INDIVIDUAL TUMOR WEIGHTS




Fig. 24

MOUSE Gli-1 EXPRESSION IN 5E1-TREATED RT-4 TUMORS

MOUSE Gli-1 EXPRESSION IN RT-4 TUMORS

MOUSE Gli-1 IN RT-4 COLONS






Fig. 25

Shh IS EXPRESSED IN PROSTATE CANCER

H377



H373



Shh a/s

Shh s

Fig. 26




Fig. 27

HH SIGNALING IN PROSTATE CANCER CELL LINES (1d in 10% FBS, 2d in 1% FBS)




Fig. 28

Gli-luc ASSAY ON PROSTATE CANCER CELL LINES
(S12 + CANCER CELL CO-CULTURES, 1d IN 10% FBS, 2d IN 1% FBS)




Fig. 29

30/37

ENCLOSURE

IN VITRO EFFICACY
INHIBITION OF HEDGEHOG SIGNALING BY HEDGEHOG ANTAGONISTS
(Gli-luc, 24 hrs)

5E1




Fig. 30

EXPRESSION OF Shh IN THE PROSTATIC EPITHELIUM AND STROMA




Fig. 31

BEST AVAILABLE COPY

32/37

EXPRESSION OF Gli-1 IN THE PROSTATIC STROMA (LifeSpan)




Fig. 32

PROXIMO-DISTAL Shh GRADIENT IN NORMAL PROSTATE




Fig. 33

HEDGEHOG SIGNALING IN BPH BY Q-RT-PCR




Fig. 34

HIGH LEVEL HEDGEHOG SIGNALING IN BPH CELL LINES




Fig. 35

EFFECT OF 5E1 ON HT-29/10T1/2 COLON CANCER GROWTH




Fig. 36

BEST AVAILABLE COPY

EFFECT OF 5E1 ON HT-29/10T 1/2 COLON CANCER GROWTH




Fig. 37